Cargando…

IL6R-STAT3-ADAR1 (P150) interplay promotes oncogenicity in multiple myeloma with 1q21 amplification

1q21 amplification is an important prognostic marker in multiple myeloma. In this study we identified that IL6R (the interleukin-6 membrane receptor) and ADAR1 (an RNA editing enzyme) are critical genes located within the minimally amplified 1q21 region. Loss of individual genes caused suppression t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Teoh, Phaik Ju, Chung, Tae-Hoon, Chng, Pamela Y.Z., Toh, Sabrina H. M., Chng, Wee Joo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193471/ https://www.ncbi.nlm.nih.gov/pubmed/31413087 http://dx.doi.org/10.3324/haematol.2019.221176

Ejemplares similares

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2022)

PRIMA-1 targets the vulnerability of multiple myeloma of deregulated protein homeostasis through the perturbation of ER stress via p73 demethylation
por: Teoh, Phaik Ju, et al.
Publicado: (2016)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

p150 ADAR1 isoform involved in maintenance of HeLa cell proliferation
por: Wang, Haifang, et al.
Publicado: (2006)

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

RNA editing of AZIN1 coding sites is catalyzed by ADAR1 p150 after splicing
por: Xing, Yanfang, et al.
Publicado: (2023)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

Janus Kinase Signaling: Oncogenic Criminal of Lymphoid Cancers
por: Li, Boheng, et al.
Publicado: (2021)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Applying Human ADAR1p110 and ADAR1p150 for Site-Directed RNA Editing—G/C Substitution Stabilizes GuideRNAs against Editing
por: Heep, Madeleine, et al.
Publicado: (2017)

Evaluation of the Interplay between the ADAR Editome and Immunotherapy in Melanoma
por: Tusup, Marina, et al.
Publicado: (2021)

Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma
por: Xiong, Sinan, et al.
Publicado: (2021)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

The p150 Isoform of ADAR1 Blocks Sustained RLR signaling and Apoptosis during Influenza Virus Infection
por: Vogel, Olivia A., et al.
Publicado: (2020)

The Interplay between RNA Editing Regulator ADAR1 and Immune Environment in Colorectal Cancer
por: Zheng, Guo-Liang, et al.
Publicado: (2023)

YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes
por: Lorenzetto, Erica, et al.
Publicado: (2014)

Gain/Amplification of Chromosome Arm 1q21 in Multiple Myeloma
por: Hanamura, Ichiro
Publicado: (2021)

Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges
por: Sklavenitis-Pistofidis, Romanos, et al.
Publicado: (2022)

ADAR1 has an oncogenic function and can be a prognostic factor in cervical cancer
por: Nakamura, Keiichiro, et al.
Publicado: (2023)

The ADAR1 editome reveals drivers of editing-specificity for ADAR1-isoforms
por: Kleinova, Renata, et al.
Publicado: (2023)

Targeting NF-κB Signaling for Multiple Myeloma
por: Wong, Ada Hang-Heng, et al.
Publicado: (2020)

Potential Clinical Application of Genomics in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2018)

A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma
por: Chung, Tae-Hoon, et al.
Publicado: (2013)

Genomic characterization of functional high-risk multiple myeloma patients
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2022)

Tumor-Associated Macrophages and Related Myelomonocytic Cells in the Tumor Microenvironment of Multiple Myeloma
por: Wang, Samuel S. Y., et al.
Publicado: (2022)

Generation of a new Adar1p150(−/−) mouse demonstrates isoform-specific roles in embryonic development and adult homeostasis
por: Liang, Zhen, et al.
Publicado: (2023)

The oncogenic E3 ligase TRIP12 suppresses epithelial–mesenchymal transition (EMT) and mesenchymal traits through ZEB1/2
por: Lee, Kwok Kin, et al.
Publicado: (2021)

Identification of novel interacts partners of ADAR1 enzyme mediating the oncogenic process in aggressive breast cancer
por: Binothman, Najat, et al.
Publicado: (2023)

Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis
por: Anadón, C, et al.
Publicado: (2016)

The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies
por: Arora, Loukik, et al.
Publicado: (2018)

Extensive editing of cellular and viral double-stranded RNA structures accounts for innate immunity suppression and the proviral activity of ADAR1(p150)
por: Pfaller, Christian K., et al.
Publicado: (2018)

ADAR1 restricts LINE-1 retrotransposition
por: Orecchini, Elisa, et al.
Publicado: (2017)

Erratum: Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis
por: Anadón, C, et al.
Publicado: (2016)

P830: IDENTIFICATION OF NOVEL TARGET GENES CORRELATED WITH 1Q21 AMPLIFICATION IN PATIENTS WITH SMOLDERING MYELOMA AND MULTIPLE MYELOMA
por: Thomas Iannozzi, Nicolas, et al.
Publicado: (2023)

P833: MARCH5 AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA
por: Bashiri, Hamed, et al.
Publicado: (2023)

Bortezomib-related neuropathy may mask CNS relapse in multiple myeloma: A call for diligence
por: Abid, Muhammad Bilal, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6rtm1qm9agsvotaee2g501to7a